加载中
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
常规交易时段
US$0.415
−US$0.0302 · -6.78%
盘中时间采用ET。市场数据可能有所延迟。
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
日内区间
当前US$0.415
52周区间
当前US$0.415
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
60
合理估值
情绪
53
多空交织
风险
73
高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
日内区间
当前US$0.415
52周区间
当前US$0.415
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 279万 USD | 22.6万 USD | 22.6万 USD | 22.6万 USD | 22.6万 USD |
| 销货成本 | — | 1.2万 USD | — | — | — |
| 毛利 | 279万 USD | 21.4万 USD | 22.6万 USD | 22.6万 USD | 22.6万 USD |
| 研究与开发 | 1214.3万 USD | 1.3亿 USD | 1143万 USD | 1140.6万 USD | 729.7万 USD |
| 销售、一般及管理费用 | 852.2万 USD | 1228.9万 USD | 909.4万 USD | 844.7万 USD | 942.5万 USD |
| 营业费用 | 2066.5万 USD | 4956.2万 USD | 2052.4万 USD | 1985.3万 USD | 1672.2万 USD |
| 折旧和摊销 | 6.1万 USD | 1.2万 USD | 1.6万 USD | 1.4万 USD | 1.4万 USD |
| 营业利润 | −1787.5万 USD | −4934.8万 USD | −2029.8万 USD | −1962.7万 USD | −1649.6万 USD |
| 净利润 | 917万 USD | −5467.4万 USD | −1894.8万 USD | −1896.4万 USD | −1616.3万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$1.00
上涨空间 140.96%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年9月23日 | 1:25 | — | — |
股票拆分 | 2021年5月21日 | 1:15 | — | — |
股票拆分 | 2018年9月26日 | 1:15 | — | — |
股票拆分 | 2016年6月1日 | 1:10 | — | — |
已生效 2024年9月23日
1:25
已生效 2021年5月21日
1:15
已生效 2018年9月26日
1:15
已生效 2016年6月1日
1:10
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
